FULC - CIK 0001680581
The table below shows Fulcrum Therapeutics, Inc.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $50.26M | $47.08M | $42.59M | $42.18M | $72.63M | $86.70M |
| Short-term investments | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $338.67M |
| $205.86M |
| $219.37M |
| $232.56M |
| $267.49M |
| $280.29M |
| Property, plant & equipment | $2.49M | $3.17M | $3.27M | $3.55M | $4.22M | $4.41M |
| Goodwill | - | - | - | - | - | - |
| Total assets | $346.77M | $214.86M | $228.84M | $242.65M | $279.01M | $294.26M |
| Accounts payable | $2.45M | $2.86M | $1.75M | $1.51M | $4.04M | $3.58M |
| Total current liabilities | $9.86M | $11.63M | $8.98M | $8.10M | $14.51M | $12.70M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $13.47M | $16.49M | $14.46M | $14.16M | $21.72M | $20.47M |
| Retained earnings | -$613.17M | -$573.94M | -$554.35M | -$537.05M | -$502.83M | -$481.13M |
| Total equity | $333.30M | $198.37M | $214.38M | $228.49M | $257.29M | $273.79M |